jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Oct. 18, 2010

Dec. 17, 2018

jRCT2080221270

A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis

A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis

ONO PHARMACEUTICAL CO.,LTD.

y.tani@ono.co.jp

343

Interventional

dose-blind, randomized

2

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer.

18age old over
55age old under

Both

Relapsing-Remitting Multiple Sclerosis

investigational material(s)
Generic name etc : ONO-4641
INN of investigational material :
Therapeutic category code : 399 Agents affecting metabolism, n.e.c.
Dosage and Administration for Investigational material : Patients will receive an oral tablet (0.05, 0.1 or 0.15 mg)once per day at about the same time.

the long-term safety and tolerability of ONO-4641

the number of Gd-enhanced lesions, lesion volume, and brain volume obtained by MRI

ONO PHARMACEUTICAL CO.,LTD.

JapicCTI-101307

History of Changes

No Publication date
12 Dec. 17, 2018 (this page) Changes
11 May. 23, 2017 Detail Changes
10 May. 23, 2017 Detail Changes
9 July. 10, 2013 Detail Changes
8 July. 10, 2013 Detail Changes
7 July. 02, 2012 Detail Changes
6 July. 02, 2012 Detail Changes
5 June. 14, 2011 Detail Changes
4 June. 14, 2011 Detail Changes
3 April. 21, 2011 Detail Changes
2 Oct. 18, 2010 Detail Changes
1 Oct. 18, 2010 Detail